Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death in First-Line Treatment for HER2-positive Advanced or Metastatic Breast Cancer By Ogkologos - November 3, 2025 261 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Breast09 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Italian Association of Oncology Nurses Maps the Situation of Cancer Patients... July 23, 2020 New Research Looks for More Effective Breast Cancer Treatments for Black... January 12, 2021 Targeted Therapy Cabozantinib Slows Progression of Rare Kidney Cancer March 24, 2021 ESMO Welcomes European Parliament (EP) Draft Report on Psychosocial Risks at... April 2, 2026 Load more HOT NEWS Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients... Navigating Your Care During Long-Term Cancer Survivorship The most important cancer research stories of 2022 Atlantic rowing trio smash world record and raise thousands for cancer...
